Physician profile
Christopher Ventura
NPI 1417634528
$2,009.83
in general payments reported to CMS, 2019-2025
28 companies · $960 in 2025
The $960 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $251 · 2024: $800 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,009.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $405.10 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $290.81 | 2023-2025 | |
| Novo Nordisk INC | $180.40 | 2023-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $159.23 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $124.99 | 2025 | Repatha |
| Merck Sharp & Dohme LLC | $107.11 | 2023-2025 | Verquvo, Belsomra |
| Otsuka America Pharmaceutical, INC. | $77.19 | 2023-2025 | Rexulti, Nuedexta |
| Sumitomo Pharma America, INC. | $71.56 | 2024-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $55.00 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $49.33 | 2025 | Recorlev |
| Baxter Healthcare | $48.46 | 2023 | Hillrom - Connex Spot Monitor |
| Lilly USA, LLC | $39.18 | 2024-2025 | Mounjaro, Zepbound |
| Ardelyx, INC. | $34.68 | 2024-2025 | Ibsrela |
| Corcept Therapeutics | $33.55 | 2023 | Korlym |
| Renalytix Ai, INC. | $33.06 | 2023-2025 | Kidneyintelx Blood Collection Convenience Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $32.35 | 2023-2025 | Rexulti |
| Kiniksa Pharmaceuticals International, Plc | $28.14 | 2024 | Arcalyst |
| Novartis Pharmaceuticals Corporation | $27.09 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $26.34 | 2024 | Evkeeza |
| Neurelis, INC. | $25.01 | 2025 | Valtoco |
| Dexcom, INC. | $24.89 | 2024 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $24.52 | 2024 | Injectafer |
| Ani Pharmaceuticals, INC. | $24.06 | 2025 | Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $22.78 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.04 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $16.11 | 2024 | Arexvy, Trelegy Ellipta |
| Corium, LLC | $15.21 | 2023 | Adlarity |
| Currax Pharmaceuticals LLC | $14.64 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ventura listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.